| Name | Title | Contact Details |
|---|
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class - while empowering our community to take control of diabetes.
Luminetx Corporation is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Oasis Medical is a Glendora, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Fonar Corporation (Fonar) operates in two business segments: medical equipment segment, and physician management and diagnostic services segment. Fonar is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance